Quantalife Lands $17,200,000 Series B Financing Round
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=9dbfe564-1c87-41f2-a714-8fb1060017b0&Preview=1 -
Date
12/13/2010 -
Company Name
Quantalife -
Mailing Address
7068 Koll Center Parkway Pleasanton, CA 94566 -
Company Description
QuantaLife, Inc. was formed to develop, manufacture and market a revolutionary nucleic acid testing concept for the Life Science Research, Clinical Molecular Diagnostics, Personalized Medical Care and Industrial markets. Our suite of products, which are based on our proprietary nucleic acid testing method, will enable rapid detection and quantification of nucleic acids in complex samples on a flexible, automated instrument. This technology provides an order of magnitude improvement in performance over current platforms at a fraction of the cost. QuantaLife is a small biotechnology startup involved in the early development phases of the technology. -
Website
http://www.quantalife.com -
Transaction Type
Venture Equity -
Transaction Amount
$17,200,000 -
Transaction Round
Series B -
Proceeds Purposes
The majority of the proceeds will be used to establish commercial operations for introduction of its first product, the Droplet Digital PCR platform, into the life sciences research market early next year and accelerate development of targeted diagnostic tests. -
M&A Terms
-
Venture Investor
Paladin Capital Group -
Venture Investor
Undisclosed
